Radyus Research says partnership with trials contactor Dt&CRO will help South Korean biotechs access US market.
The accord – financial terms of which were not disclosed – will aim to help South Korean drug developers navigate US regulatory processes, initiate IND applications and conduct first-in-human trials according to Radyus CEO, Marta New.
"At Radyus Research, we are thrilled to partner with Dt&CRO to empower their sponsor companies, which are ambitious and innovative biotech companies from South Korea.
“Our collaboration will provide invaluable support and guidance, enabling South Korean innovators to navigate regulatory processes, initiate IND applications, and conduct first-in-human trials in the US. These critical steps are essential for South Korean biotech companies to establish a strong presence in this market and attract investment from international stakeholders,” she said.
Korea’s biotechnology sector is growing fast. According to Government-backed agency Invest Korea – which is worth an estimate KRW 21 trillion – has increased in value nearly 18% a year over the past half-decade.
Local lab
Dt&CRO was set up in 2017, opening a bio-analysis center in January 2018 and a non-clinical trial centre in November. The firm offers a range of preclinical and clinical trial services for new drugs, biosimilar and generics.
With this in mind, the new agreement will also see Dt&CRO provide Radyus’ biopharmaceutical industry clients with local non-GLP and GLP laboratory testing services.
CEO, Chaegyu Park, said "By combining our expertise in laboratory testing with Radyus Research's comprehensive support for drug development and regulatory strategy, we can offer a holistic solution that meets the needs of biotech innovators in South Korea and enhances our global CRO competitiveness."
The Dt&CRO partnership is in keeping with the growth strategy Radyus has followed in recent times. In March, for example, the Atlanta CRO teamed with Georgia-based neighbour Southern Research.
Unsplash/homajob